Baseline demographics of rituxilup cohort
| Patient no. | Sex | Age | LN class | Ethnicity | dsDNA antibodies | Low C3+/or C4 | Non-renal symptoms | Previous treatment |
|---|---|---|---|---|---|---|---|---|
| 1 | M | 54 | V | Caucasian | − | − | – | Tac |
| 2 | M | 31 | V | Asian* | − | − | – | – |
| 3 | F | 29 | IV | Caucasian | + | + | G, MC, MS, N | CS, MMF, CyP, HCQ |
| 4 | F | 25 | V | Afro-Caribbean | + | − | MC, H | – |
| 5 | F | 46 | IV | Asian* | + | + | G, H | – |
| 6 | F | 26 | IV+V | Asian* | + | + | MC, MS | HCQ |
| 7 | M | 54 | V | Oriental | − | − | H | HCQ |
| 8 | M | 52 | IV | Caucasian | + | − | H | HCQ, MTX |
| 9 | F | 67 | IV | Caucasian | − | + | – | – |
| 10 | F | 74 | V | Caucasian | − | + | H | − |
| 11 | F | 47 | V | Caucasian | − | − | − | CS, Aza, Tac |
| 12 | F | 28 | IV | Oriental | − | − | MC, H | – |
| 13 | F | 60 | IV | Caucasian | + | + | H | – |
| 14 | F | 43 | III | Asian* | + | − | MC | – |
| 15 | F | 30 | V | Afro-Caribbean | + | − | H | CS, HCQ |
| 16 | M | 46 | V | Caucasian | − | − | – | – |
| 17 | M | 69 | V | Afro-Caribbean | − | − | – | – |
| 18 | F | 66 | V | Caucasian | − | + | – | CS, Aza |
| 19 | F | 39 | IV | Caucasian | + | + | G, MC, MS, H, N | HCQ |
| 20 | M | 20 | IV | Caucasian | + | + | H | CS, Aza |
| 21 | M | 61 | V | Asian* | − | − | – | – |
| 22 | M | 19 | V | Caucasian | − | − | – | CS |
| 23 | F | 46 | IV+V | Afro-Caribbean | + | + | H | – |
| 24 | F | 73 | V | Caucasian | − | − | – | – |
| 25 | F | 50 | IV+V | Asian* | + | + | G, MC, MS, H | CS, HCQ |
| 26 | F | 42 | V | Afro-Caribbean | − | − | H | – |
| 27 | F | 59 | V | Mixed | + | − | – | CS |
| 28 | F | 33 | III | Mixed | + | + | – | CS, HCQ |
| 29 | M | 69 | V | Asian* | − | − | – | – |
| 30 | F | 55 | V | Asian* | + | + | MC, H | CS, MMF, Aza |
| 31 | F | 34 | IV | Oriental | + | + | H | – |
| 32 | F | 46 | IV | Caucasian | − | + | H | – |
| 33 | F | 36 | III | Caucasian | + | + | MC, MS | CS, HCQ |
| 34 | F | 75 | V | Asian* | − | − | – | – |
| 35 | F | 53 | V | Caucasian | − | − | – | – |
| 36 | F | 29 | III+V | Caucasian | + | + | MC, MS, H | CS, MMF, HCQ, Aza |
| 37 | F | 31 | III+V | Asian* | − | + | H | HCQ |
| 38 | F | 26 | IV+V | Oriental | + | + | H | – |
| 39 | F | 24 | III | Caucasian | − | − | – | CS, MMF |
| 40 | F | 30 | III | Asian* | + | + | MS, H, CR | HCQ |
| 41 | F | 38 | V | Asian* | − | − | – | – |
| 42 | F | 48 | V | Mixed | + | + | H | CS, Aza |
| 43 | F | 30 | IV | Asian* | + | + | G, H | CS |
| 44 | F | 25 | IV | Asian* | + | + | G, MC, MS, H, CR | – |
| 45 | F | 25 | IV | Oriental | + | + | – | – |
| 46 | F | 67 | IV | Caucasian | − | − | – | – |
| 47 | M | 19 | IV | Afro-Caribbean | + | + | G, MS, H | – |
| 48 | F | 19 | IV | Mixed | − | − | – | – |
| 49 | F | 68 | III+V | Asian* | + | + | G, MC | CS, CyP, HCQ |
| 50 | F | 70 | V | Caucasian | − | − | – | – |
*Asian denotes individuals from Indian subcontinent.
Double-stranded DNA antibody (dsDNA Ab) quantitative assay: negative <30 μ/ml: Low C3 <0.7 g/litre; Low C4 <0.16 g/litre.
Non-renal symptoms (as described in the British Isles Lupus Assessment Group (BILAG) Index23): CR, cardiorespiratory; G, general; H, haematological; MC, mucocutaneous; MS, musculoskeletal; N, neurological.
Previous treatments: Aza, azathioprine; CS, corticosteroids; CyP, cyclophosphamide; HCQ, hydroxychloroquine; LN, lupus nephritis; MMF, mycophenolate mofetil; MTX, methotrexate; Tac, tacrolimus.